Trial record 1 of 291895 for:    ALL
Previous Study | Return to List | Next Study

Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03771157
Recruitment Status : Not yet recruiting
First Posted : December 10, 2018
Last Update Posted : December 10, 2018
Information provided by (Responsible Party):
Jonathan Friedberg, University of Rochester

No Study Results Posted on for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : January 1, 2021
  Estimated Study Completion Date : January 1, 2021